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Background
The effect of pharmacological treatment on cognition is
still uncertain due to an insufficient number of studies
examining this issue.
Materials and methods
A total of 114 subjects were included in the study. Of 79
DSM-IV euthymic bipolar patients, 63 were treated with
one atypical antipsychotic, quetiapine (n = 12), olanza-
pine (n = 22), or risperidone (n = 29). Sixteen patients
were drug-free. The four groups were compared with a
sample of drug-naïve patients and healthy control group
(n = 35) on several clinical and neuropsychological vari-
ables, especially on the domains of attention, verbal
memory and executive functions.
Results
Bipolar patients taking one of the three antipsychotics
presented with dose-independent significant deficits in
most cognitive tasks compared to healthy controls. After
several head-to-head group comparisons, the patients
receiving quetiapine showed a better performance in
learning task, short-term memory and recognition task
assessed with the California Verbal Learning Test and
verbal fluency (p < 0.05).
Conclusions
Our results confirm previous studies of cognitive deficits
in bipolar disorder. Untreated euthymic patients showed
better cognitive performancet h a np a t i e n t so na t y p i c a l
antipsychotics. Some iatrogenic-pharmacological effect,
therefore, can not be excluded but quetiapine seemed to
be less associated with impairment in measures of verbal
memory than olanzapine or risperidone. We suggest to
use drugs in bipolar disorder with a lower risk of
cognitive side-effects. However, randomized controlled
t r i a l sa r eu r g e n t l yn e e d e dt og i v ead e f i n i t ea n s w e rt o
this critical problem.
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